MyAllies NewsBreakingRegulatoryWorldTechnologyBusinessPoliticsEntertainmentHealthSportsTopics
Home › Regulatory

bioAffinity Technologies, Inc. - 10-Q Filing

bioAffinity Technologies reports Q3 2026 financial results including revenue from histology service fees and CyPathLung services.

3 articles from 1 source · updated November 9, 2026, 13:04 UTC

Coverage

  • RB GLOBAL INC. - 10-Q Filing SEC EDGAR · November 9, 2026, 13:03 UTC
  • Tango Therapeutics, Inc. - 10-Q Filing SEC EDGAR · November 9, 2026, 12:11 UTC
  • bioAffinity Technologies, Inc. - 10-Q Filing SEC EDGAR · November 6, 2026, 22:27 UTC